Editor's ASCO 2016 Roundup

Inpatient palliative care intervention in patients hospitalized for HSCT

Latest in precision cancer medicine

The value and strategy for incorporating biosimilars Into clinical practice

Checkpoint inhibitor therapy benefits advanced bladder cancer patients

Neuroblastoma outcomes improved with second stem cell transplant

Adjuvant docetaxel fails after radical prostatectomy for high risk prostate cancer

Sequencing analysis with circulating DNA

Consolidative therapy extends PFS for NSCLC patients

Preliminary results from KEYNOTE-055: pembrolizumab in HNSCC

Targetting PD-L1 with avelumab in metastatic Merkel cell carcinoma

Cochlear sparing via intensity modulated radiotherapy

Ten years of letrozole improves survival and quality of life in early-diagnosed breast cancer.

Daratumumab slows progression in refractory multiple myeloma

Developments in haematological malignancies

Early integrated palliative care to improve family caregivers outcomes

Recent developments in targeted therapies

First results of a prospective bendamustine/rituximab trial in patients with MCL

Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers

MyPathway guidance of targeted therapy based on molecular profiles

Testing the safety and efficacy of the PD-L1 antibody durvalumab

Upfront autologous stem cell transplantation for newly diagnosed multiple myeloma

Subset of anaplastic glioma patients benefit from adjuvant chemo

ASCO 2016: What is the optimal chemotherapy dosing regimen for prostate cancer?

Advanced RET-rearranged NSCLC

Global drug pricing: How cost-effective is bevacizumab?

Update on olaparib in ovarian cancer

CPX-351 improves outcomes for refractory AML

Radiotherapy modalities for locally advanced non-small cell lung cancer

First in-human trials of rovalpituzumab for SCLC

Impact of precision medicine in refractory malignancies

Large disparities found in BCRA testing across ethnicities

Surgery in stage 4 breast cancer increased survival

Trial shows exercise beneficial for patients undergoing chemotherapy

Photon vs proton beam therapy: modality in radiotherapy for non-small cell lung cancer

Phase I study of sapacitabine and seliciclib in patients with advanced solid tumours

ASCO 2016: Plenary Session Review

Elderly patients with glioblastoma live longer with chemoradiation using temozolomide

Chemotherapy combination with capecitabine extends survival after pancreatic cancer surgery

Primary tumour location in metastatic colorectal cancer impacts overall survival

Novel antibody helps patients with advanced gastric cancer live longer

Antibody drug conjugate shows early promise in small cell lung cancer

Novel antibody helps patients with advanced gastric cancer live longer

Patients with advanced bladder cancer benefit from anti-PD-L1 immunotherapy

METEOR trial: cabozantinib vs everolimus in advanced renal cell carcinoma

Extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone

Ten years of hormone therapy reduces breast cancer recurrence without compromising quality of life

Elderly patients with glioblastoma live longer with chemoradiation using temozolomide

Novel daratumumab-based regimen slows multiple myeloma progression

Double stem-cell transplant improves outcomes for children with high-risk neuroblastoma

Patient engagement in The Metastatic Breast Cancer Project

Advanced hepatocellular carcinoma and personalised therapy

Latest in hepatocellular carcinoma treatments

Intraperitoneal chemotherapy slows ovarian cancer progression

Liquid biopsy may help guide treatment decisions for advanced solid tumours

Innovative direct-to-patient outreach may accelerate breast cancer research

Precision medicine selection with MyPathway for solid tumours

Liquid biopsy may help guide treatment decisions for advanced solid tumours

ASCO 2016: Expert discussion on the latest on multiple myeloma

Trial of proposed trastuzumab biosimilar, MYL-1401O vs herceptin

Hypo-fractionation of prostate cancer radiotherapy

Controlled phase III trial of adjuvant combination chemotherapy of gemcitabine and capecitabine, versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Randomised double blind phase III safety and efficacy trial of the proposed trastuzumab biosimilar, MYL-1401O vs. herceptin

Phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

Temozolomide after radiotherapy improves glioma survival